Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - NOVEMBER 2013

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Lisinopril -Tablets
Aliskiren - Tablets
Aliskiren and Amlodipine - Tablets
Aliskiren and Hydrochlorothiazide - Tablets
Aliskiren, Amlodipine and Hydrochlorothiazide - Tablets
Chloroquine - Tablets
Clobazam - Tablets and Oral Suspension
Crizotinib - Capsules
Daptomycin - for Injection
Golimumab - Injection
Infliximab - Lyophilized Concentrate for Injection
Lanreotide - Injection
Lansoprazole - 30 mg Delayed-Release,
Amoxicillin - 500 mg Capsules and Clarithromycin - 500 mg Tablets
Lenalidomide - Capsules
Mitotane - Tablets
Nitrofurantoin - Oral Suspension
Pazopanib - Tablets
Pioglitazone - Tablet
Pioglitazone - Tablets
Posaconazole - Delayed-release tablets and Oral Suspension
Sorafenib - TabletsĀ 

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Get Health and Wellness Secrets from Our Engaging eBooks
Stay Connected
Available on the Android Market Available on the App Store